July 3, 2026

Vanderbilt Center for Cognitive Medicine seeks participants for trial evaluating Alzheimer’s disease-related psychosis treatment

The ADEPT-4 study evaluates KarXT, an oral medication that may reduce hallucinations and delusions.

By Danny Bonvissuto